APLUSA

#ESMO24 📅 Save the date! We are delighted to announce our participation in the upcoming ESMO - European Society for Medical Oncology 2024 congress, which will take place September 13-17, 2024 in Barcelona. The ESMO congress is one of the world's leading events in the field of oncology, bringing together leading experts and cutting-edge research. Our international experts look forward to meeting you and discussing advances in oncology! Stop by our booth #430 and say hi! Are you attending #ESMO24? 👋 Come to us and let's connect!

📰 #Melanoma | Impact of High-Dose Vitamin D Supplementation on Outcomes Among Patients With Curatively Resected Cutaneous Melanoma "This double-blind placebo-controlled trial investigated the impact of high-dose vitamin D supplementation on relapse rates among patients with curatively resected cutaneous melanoma. [...]" 👇 https://hubs.ly/Q02KBSDb0

🎓 Vous souhaitez former vos chargé(e)s d'études ? APLUSA organise une nouvelle session de la formation Ad Hoc Santé le 𝟯𝟬 𝘀𝗲𝗽𝘁𝗲𝗺𝗯𝗿𝗲 et 𝟭𝗲𝗿 𝗼𝗰𝘁𝗼𝗯𝗿𝗲 𝟮𝟬𝟮𝟰. 𝗔𝗗 𝗛𝗢𝗖 𝗦𝗔𝗡𝗧𝗘 est une formation complète sur 2 jours, destinée aux nouvelles équipes chargées d'études de marché dans l'industrie pharmaceutique. Cette formation se déroule en immersion (repas et nuit sur place) dans un cadre unique et inspirant, au Château de Mareil-le-Guyon (78). Elle est animée par nos experts en études de marché et en statistiques avancées. Cette formation interactive permet d'acquérir les connaissances nécessaires à la gestion des projets d'étude, depuis le brief agence jusqu'à la valorisation des résultats en interne, en s'appuyant sur des exercices en co-construction. Complétez dès aujourd'hui ce formulaire pour vous inscrire à la prochaine session qui sera organisée les 30 septembre et 1er octobre 2024.👇https://hubs.ly/Q02CCWYT0

📰 #DLBCL | Autologous Transplant vs CAR T-Cell Therapy in Patients With DLBCL in Complete Remission "CAR T-cell (CAR-T) therapy is widely established as a standard of care for relapsed or refractory (R/R) DLBCL. In many instances, due to the duration of time required to arrange T-cell collection and manufacture the CAR T-cell product, patients require “bridging therapy,” consisting of chemoimmunotherapy or radiation therapy, to temporarily treat their disease while waiting for CAR-T treatment. In some cases, this bridging treatment results in a complete remission (CR) prior to receiving CAR-T therapy. [...]" 👇 https://hubs.ly/Q02KBcDH0

#EHA24 | Have you discovered our posters presented at EHA? If not, it is time to find out! Last June, our research has been recognized and we have had two posters presented during EHA Congress in Madrid 2024! 🌟 📍 Poster 1: Current use of salvage 2nd line treatment in patients with relapsed/refractory aggressive B-cell lymphoma and key drivers for selecting therapy with CAR-T cells. Data from a real-world study in EU5. 👉 https://lnkd.in/eWKabNC3 📍 Poster 2: Current use of BCMA-targeted agents in relapsed/refractory multiple myeloma and key drivers when selecting CAR-T cells versus bispecifics. Data from real-world study in EU5 countries and in the US. 👉 https://lnkd.in/eGV4eJt5 These studies shed light on the real-world application and decision-making processes in advanced cancer therapies, reflecting our commitment to advancing knowledge and improving patient outcomes. Browse the rest of our recognized research presented at previous congresses right here 🔗https://lnkd.in/eD655iUa #EHA2024 #MultipleMyeloma #DLBCL #CancerResearch #RealWorldData #CART #BCMA #MedicalResearch #HealthcareInnovation

📰 #Obesity | Study finds lower obesity-related cancer risk in diabetics taking GLP-1s "A new study published Friday in JAMA Network Open suggests that GLP-1 receptor agonists, so far approved to treat diabetes and obesity, may have an additional benefit – reducing the risk of certain obesity-associated cancers (OACs).[...]" FirstWord Pharma https://hubs.ly/Q02Kz87f0

🎓 Le 𝟯𝟬 𝘀𝗲𝗽𝘁𝗲𝗺𝗯𝗿𝗲 𝗲𝘁 𝟭𝗲𝗿 𝗼𝗰𝘁𝗼𝗯𝗿𝗲 𝟮𝟬𝟮𝟰 se tiendra une nouvelle session de la formation Ad Hoc Santé, spécialement conçue pour les chargé(e)s d’études. Rejoignez-nous pour approfondir vos compétences et échanger avec des experts du secteur ! 𝗔𝗗 𝗛𝗢𝗖 𝗦𝗔𝗡𝗧𝗘 est une formation complète sur 2 jours, destinée aux nouvelles équipes chargées d'études de marché dans l'industrie pharmaceutique. Cette formation se déroule en immersion (repas et nuit sur place) dans un cadre unique et inspirant, au Château de Mareil-le-Guyon (78). Elle est animée par nos experts en études de marché et en statistiques avancées. Cette formation interactive permet d'acquérir les connaissances nécessaires à la gestion des projets d'étude, depuis le brief agence jusqu'à la valorisation des résultats en interne, en s'appuyant sur des exercices en co-construction. Complétez dès aujourd'hui ce formulaire pour vous inscrire à la prochaine session qui sera organisée les 30 septembre et 1er octobre 2024.👇 https://hubs.ly/Q02CCs170

📰 #AI | AI-crafted hospital discharge notes rate favourably in ER study "Discharge instructions generated by large language models (LLMs) such as ChatGPT can provide tailored guidance to patients returning home from the emergency department (ED), according to a recent study published in the Journal of Medical Internet Research.  A survey of 156 respondents representing patient populations found that they viewed GPT-generated return precautions much more favourably (P = .01) and found the rest of the GPT discharge instructions to be noninferior to standard ones. [...]" FirstWord Pharma https://lnkd.in/eCjNhGBW

🎬 #APLUSALife | Fast & Curious #6 Quali ou Quanti ? Healthcare ou haute couture ? Déjeuner d'équipe ou afterwork ? Découvrez nos directeur·rice·s de Business Unit APLUSA sous un angle inédit dans ce sixième épisode de notre série Fast & Curious, spécial DBUs ! ✨ Un grand merci à eux pour leur participation et leur bonne humeur ! Retrouvez les épisodes précédents sur notre chaîne Youtube 👇 https://hubs.ly/Q02GJvFs0 #FastAndCurious #MarqueEmployeur #DBU

🌎 #WorldLungCancerDay | Did you know that 20% of patients with Early Stage NSCLC also suffer from diabetes? August 1st is #WorldLungCancerDay. On this occasion, we would like to share an insight based on data collected by our NSCLC tracker in Q4 2023 for the United Kingdom. At APLUSA, we believe that the information collected from our studies go beyond business concerns, and serve the purpose of improving the way patients can be treated. Would you like to receive more information about NSCLCsyndiTrack™? Contact us 👉 https://hubs.ly/Q02JydlS0 Source: NSCLCsyndiTrack™ - Data collected in Q4 2023